A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

Percentage of Participants with Clinical Remission at Week 12

Clinical remission is defined as stool frequency subscore of 0 or 1, where the stool frequency subscore has not increased from baseline, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1.

Time frame: Week 12

Percentage of Participants with Symptomatic Remission at Week 12

Symptomatic remission is defined as stool frequency subscore of 0 or 1, where the stool frequency subscore has not increased from baseline, and a rectal bleeding subscore of 0.

Time frame: Week 12

Percentage of Participants with Endoscopic Improvement at Week 12

Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

Time frame: Week 12

Percentage of Participants with Histologic-endoscopic Mucosal Improvement at Week 12

Histologic-endoscopic mucosal improvement is defined as a combination of histologic remission and endoscopic improvement. Histologic remission and endoscopic improvement are based on the histologic grading and the Mayo endoscopy subscore.

Time frame: Week 12

Percentage of Participants with Adverse Events (AE) and Serious Adverse Evets (SAEs)

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.